The World Health Organization estimates that by the year 2040, neurodegenerative diseases will be the second leading cause of death in developed countries, overtaking cancer-related deaths and exceeded only by cardiovascular disease–related death. The search for interventions has therefore become paramount to alleviate some of this burden. Based on pathways affected in neurodegenerative diseases, hyperbaric oxygen treatment (HBOT) could be a good candidate. This therapy has been used for the past 50 years for conditions such as decompression sickness and wound healing and has been shown to have promising effects in conditions associated with neurodegeneration and functional impairments. The goal of this review was to explore the history of hyperbaric oxygen therapy, its uses, and benefits, and to evaluate its effectiveness as an intervention in treating neurodegenerative diseases. Additionally, we examined common mechanisms underlying the effects of HBOT in different neurodegenerative diseases, with a special emphasis on epigenetics.
Mensah-Kane, Paapa, Sumien, Nathalie. The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases. // GeroScience. – 2023. – DOI: 10.1007/s11357-022-00707-z. – URL: http://link.springer.com/openurl/fulltext?id=doi:10.1007/s11357-022-00707-z
Mensah-Kane, Paapa, Sumien, & Nathalie (2023). The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases. GeroScience. https://doi.org/10.1007/s11357-022-00707-z
Mensah-Kane, et al. “The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases.” GeroScience, 2023. doi:10.1007/s11357-022-00707-z.
@article{MensahKane2023,
title = {The potential of hyperbaric oxygen as a therapy for neurodegenerative diseases},
author = {Mensah-Kane and Paapa and Sumien and Nathalie},
journal = {GeroScience},
year = {2023},
doi = {10.1007/s11357-022-00707-z},
url = {http://link.springer.com/openurl/fulltext?id=doi:10.1007/s11357-022-00707-z}
}
Extreme longevity is accompanied by cardiac molecular remodelling, yet the basis of sex-associated adaptation during late-life aging remains incompletely understood. Here, we performed cardiac proteomic and multi-compartment metabolomic...
Plasma biomarkers for Alzheimer’s disease (AD) on fully automated platforms offer accessible, cost-effective diagnostic tools. Here we aimed to compare Lumipulse plasma phospho-tau217 (p-tau217) and the p-tau217/beta-amyloid42 ratio...
Aging natural killer (NK) cells might retain their killing machinery yet struggle to deploy it. Liu and colleagues now link this defect to retinoid-associated lipid remodeling, and show that inhibiting fatty acyl chain elongation...